Adrenergic action in breast cancer

Current Cancer Therapy Reviews

Volumn 8, Issue 2, 2012, Pages 90-99

  Lüthy, Isabel Alicia ^a   Bruzzone, Ariana ^a   Piñero, Cecilia Pérez ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Adrenoceptors; Breast cancer; Human; Mammary tumor; Mouse; Rauwolscine; Yohimbine

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; AROMATASE INHIBITOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CATECHOLAMINE; CLONIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DOPAMINE BETA MONOOXYGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; G PROTEIN COUPLED RECEPTOR; GONADORELIN AGONIST; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; NORADRENALIN; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PROGESTERONE; PROTEIN KINASE B; RALOXIFENE; RAUWOLSCINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG; YOHIMBINE;

ADRENERGIC ACTIVITY; ALCOHOL CONSUMPTION; ALPHA HELIX; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMOSOMAL LOCALIZATION; DRUG RECEPTOR BINDING; DRUG TARGETING; GENETIC POLYMORPHISM; HER2 ENRICHED BREAST CANCER; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRON; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MENARCHE; MENOPAUSE; MOLECULAR LIBRARY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NONHUMAN; NULLIPARA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR UPREGULATION; RECURRENCE RISK; RISK REDUCTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

EID: 84861785309     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339412800675397     Document Type: Article

References (82)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Jemal A, Bray F, Center MM., et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-52.
4. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-502.
5. Wolters R, Regierer AC, Schwentner L, et al. A comparison of international breast cancer guidelines -Do the national guidelines differ in treatment recommendations? Eur J Cancer 2012; 48(1): 1-11.
6. Bedard PL, Cardoso F. Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nat Rev Clin Oncol 2011; 8(5): 272-9.
7. Lumachi F, Luisetto G, Basso SM, et al. Endocrine therapy of breast cancer. Curr Med Chem 2011; 18(4): 513-22.
8. Valabrega G, Capellero S, Cavalloni G, et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 2011; 130(1): 29-40.
9. Gennari A, Stockler M, Puntoni M, et al. Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials 2011; 29(16): 2144-9.
10. Davies E, Hiscox S. New therapeutic approaches in breast cancer. Maturitas 2011; 68(2): 121-8.
11. Zhang S, Huang WC, Li P, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17(4): 461-9.
12. Saxena M, Stephens MA, Pathak H, et al. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011; 2: e179.
13. Rasmussen SG, Choi HJ, Rosenbaum DM, et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007; 450(7168): 383-7.
14. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of biobehavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006; 6(3): 240-8.
15. Knaus AE, Muthig V, Schickinger S, et al. alpha(2)-Adrenoceptor subtypes-Unexpected functions for receptors and ligands derived from gene-targeted mouse models. NeurochemInt 2007; 51: 277-81.
16. Dixon RA, Kobilka BK, Strader DJ, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986; 321(6065): 75-9.
17. Brodde OE. Beta1and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol 2008; 22(2): 107-25.
18. Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318(5854): 1258-65.
19. Rasmussen SG, Choi HJ, Fung JJ, et al. Structure of a nanobodystabilized active state of the beta(2) adrenoceptor. Nature 2011; 469(7329): 175-80.
20. Rosenbaum DM, Zhang C, Lyons JA, et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011; 469(7329): 236-40.
21. Kobilka BK, Matsui H, Kobilka TS, et al. Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science 1987; 238(4827): 650-6.
22. Lomasney JW, Lorenz W, Allen LF, et al. Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA 1990; 87(13): 5094-8.
23. Regan JW, Kobilka TS, Yang-Feng TL, et al. Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. Proc Natl Acad Sci USA 1988; 85(17): 6301-5.
24. Ruuskanen JO, Laurila J, Xhaard H, et al. Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha 2-adrenoceptors. Br J Pharmacol 2005; 144(2): 165-77.
25. Xhaard H, Nyronen T, Rantanen VV, et al. Model structures of alpha-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. J Struct Biol 2005; 150(2): 126-43.
26. Laurila J, Wissel G, Xhaard H, et al. Involvement of the first transmembrane segment of human alpha(2) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine. Br J Pharmacol 2011; 164(5): 1558-72.
27. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. JAllergy ClinImmunol 2006; 117(1): 18-24.
28. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res. 2010; 19(1): 45-54.
29. Philipp M, Hein L. Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol Ther 2004; 101(1): 65-74.
30. Metrich M, Laurent AC, Breckler M, et al. Epac activation induces histone deacetylase nuclear export via a Ras-dependent signalling pathway. Cell Signal 2010; 22(10): 1459-68.
31. Shenoy SK, Drake MT, Nelson CD, et al. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 2006; 281(2): 1261-73.
32. Shenoy SK, Modi AS, Shukla AK, et al. Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2. Proc Natl Acad Sci U S A 2009; 106(16): 6650-5.
33. Karkoulias G, Mastrogianni O, Papathanasopoulos P, et al. Alpha(2)-Adrenergic receptors activate cyclic AMP-response element-binding protein through arachidonic acid metabolism and protein kinase A in a subtype-specific manner. J Neurochem 2007; 103(3): 882-95.
34. Buffin-Meyer B, Crassous PA, Delage C, et al. EGF receptor transactivation and PI3-kinase mediate stimulation of ERK by alpha(2A)-adrenoreceptor in intestinal epithelial cells: A role in wound healing. Eur J Pharmacol 2007; 574: 85-93.
35. Lipworth BJ. Long-acting beta2-adrenoceptor agonists: a smart choice for asthma? Trends Pharmacol Sci 2007; 28(6): 257-62.
36. Gyires K, Zadori ZS, Torok T, et al. alpha(2)-Adrenoceptor subtypes-mediated physiological, pharmacological actions. Neurochem Int 2009; 55(7): 447-53.
37. Peeters G, Petre P, Quintelier W. Nature of adrenoceptor sites in bovine teat muscles. Naunyn Schmiedebergs Arch Pharmacol 1977; 296(2): 111-5.
38. Roets E, Vandeputte-Van Messom G, Peeters G. Relationship between milkability and adrenoceptor concentrations in teat tissue in primiparous cows. J Dairy Sci 1986; 69(12): 3120-30.
39. Roets E, Vandeputte-Van Messom G, Burvenich C, et al. Relationship between numbers of alpha 2- and beta 2- adrenoceptors in teat tissue and blood cells and milkability of primiparous cows. J Dairy Sci 1989; 72(12): 3304-13.
40. Hammon HM, Bruckmaier RM, Honegger UE, et al. Distribution and density of alpha- and beta-adrenergic receptor binding sites in the bovine mammary gland. J Dairy Res 1994; 61(1): 47-57.
41. Inderwies T, Riedl J, Kiossis E, et al. Effects of alpha- and betaadrenergic receptor stimulation and oxytocin receptor blockade on milking characteristics in dairy cows before and after removal of the teat sphincter. J Dairy Res 2003; 70(3): 289-92.
42. Inderwies T, Pfaffl MW, Meyer HH, et al. Detection and quantification of mRNA expression of alpha- and beta-adrenergic receptor subtypes in the mammary gland of dairy cows. Domest Anim Endocrinol 2003; 24(2): 123-35.
43. Franke-Radowiecka A, Wasowicz K. Adrenergic and cholinergic innervation of the mammary gland in the pig. Anat Histol Embryol 2002; 31(1): 3-7.
44. Lavandero S, Donoso E, Sapag-Hagar M. Beta-adrenergic receptors in rat mammary gland. Biochem Pharmacol 1985; 34(11): 2034-6.
45. Clegg RA, Mullaney I. Acute change in the cyclic AMP content of rat mammary acini in vitro. Influence of physiological and pharmacological agents. Biochem J 1985; 230(1): 239-46.
46. Marchetti B, Fortier MA, Poyet P, et al. Beta-adrenergic receptors in the rat mammary gland during pregnancy and lactation: characterization, distribution, and coupling to adenylate cyclase. Endocrinology 1990; 126(1): 565-74.
47. Marchetti B, Labrie F. Hormonal regulation of beta-adrenergic receptors in the rat mammary gland during the estrous cycle and lactation: role of sex steroids and prolactin. Endocrinology 1990; 126(1): 575-81.
48. Marchetti B, Spinola PG, Plante M, et al. Beta-adrenergic receptors in DMBA-induced rat mammary tumors: correlation with progesterone receptor and tumor growth. Breast Cancer Res Treat 1989; 13(3): 251-63.
49. Marchetti B, Spinola PG, Pelletier G, et al. A potential role for catecholamines in the development and progression of carcinogen- induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol 1991; 38(3): 307-20.
50. Soppa GK, Smolenski RT, Latif N, et al. Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol 2005; 288(3): H1468-76.
51. Nevzorova J, Evans BA, Bengtsson T, et al. Multiple signaling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. Br J Pharmacol 2006; 147(4): 446-54.
52. Perez-Schindler J, Philp A, Baar K, et al. Regulation of contractility and metabolic signaling by the beta2-adrenergic receptor in rat ventricular muscle. Life Sci 2011; 88(19-20): 892-7.
53. Vandewalle B, Revillion F, Lefebvre J. Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 1990; 116(3): 303-6.
54. Draoui A, Vandewalle B, Hornez L, et al. Beta-adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res 1991; 11(2): 677-80.
55. Badino GR, Novelli A, Girardi C, et al. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 1996; 33(4-5): 255-60.
56. Cakir Y, Plummer HK, III, Tithof PK, et al. Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 2002; 21(1): 153-7.
57. Plummer HK, III, Yu Q, Cakir Y, et al. Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer 2004; 4: 93.
58. Slotkin TA, Zhang J, Dancel R, et al. Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 2000; 60(2): 153-66.
59. Lang K, Drell TLt, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112(2): 231-8.
60. Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 2007; 26(26): 3777-88.
61. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70(18): 7042-52.
62. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle 2007; 6(4): 430-3.
63. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1(7): 628-38.
64. Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011; 129: 549-556.
65. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a populationbased study. J Clin Oncol 2011; 29(19): 2635-44.
66. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Betablocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29(19): 2645-52.
67. Shah SM, Carey IM, Owen CG, et al. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011; 72(1): 157-61.
68. Shi M, Liu D, Duan H, et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat 2011; 125(2): 351-62.
69. Huang XE, Hamajima N, Saito T, et al. Possible association of beta2- and beta3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer. Breast Cancer Res 2001; 3(4): 264-9.
70. Feigelson HS, Teras LR, Diver WR, et al. Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res 2008; 10(4): R57.
71. Vazquez SM, Pignataro O, Luthy IA. Alpha2-adrenergic effect on human breast cancer MCF-7 cells. Breast Cancer Res Treat. 1999; 55(1): 41-9.
72. Vazquez SM, Mladovan AG, Perez C, et al. Human breast cell lines exhibit functional alpha(2)-adrenoceptors. Cancer Chemother Pharmacol 2006; 58: 50-61.
73. Vazquez SM, Mladovan A, Garbovesky C, et al. Three novel hormone-responsive cell lines derived from primary human breast carcinomas: functional characterization. J Cell Physiol. 2004; 199(3): 460-9.
74. Bruzzone A, Pinero CP, Castillo LF, et al. Alpha(2)-Adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol 2008; 155(4): 494-504.
75. Lanari C, Luthy I, Lamb CA, et al. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 2001; 61(1): 293-302.
76. Bruzzone A, Pérez Pinero C, Rojas P, et al. 2-adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Current Cancer Drug Targets 2011; 11: 763-774.
77. Lamb CA, Fabris V, Gorostiaga MA, et al. Isolation of a stromal cell line from an early passage of a mouse mammary tumor line: a model for stromal parenchymal interactions. J Cell Physiol 2005; 202(3): 672-82.
78. Chiesa IJ, Castillo LF, Luthy IA. Contribution of alpha2-adrenoceptors to the mitogenic effect of catecholestrogen in human breast cancer MCF-7 cells. J Steroid Biochem Mol Biol 2008; 110(1-2): 170-5.
79. Lanari C, Lamb CA, Fabris VT, et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009; 16(2): 333-50.
80. Bruzzone A, Vanzulli SI, Soldati R, et al. Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J Cell Physiol 2009; 219(2): 477-84.
81. Su F, Ouyang N, Zhu P, et al. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem Biophys Res Commun 2005; 329(3): 888-97.
82. Powe DG, Voss MJ, Habashy HO, et al. Alpha- and beta- adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat 2011; 130(2): 457-63.